{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T22:06:07Z","timestamp":1779919567625,"version":"3.53.1"},"reference-count":7,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.eururo.2026.01.022","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T21:11:39Z","timestamp":1770844299000},"page":"553-554","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Re: Optimal Duration of Androgen Deprivation Therapy with Definitive Radiotherapy for Localized Prostate Cancer. A Meta-analysis"],"prefix":"10.1016","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0567-404X","authenticated-orcid":false,"given":"Alessandro","family":"Viti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0071-1868","authenticated-orcid":false,"given":"Simone","family":"Scuderi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Gandaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Montorsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2026.01.022_b0005","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/jamaoncol.2025.4800","article-title":"Optimal duration of androgen deprivation therapy with definitive radiotherapy for localized prostate cancer: a meta-analysis","volume":"12","author":"Zaorsky","year":"2026","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2026.01.022_b0010","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.eururo.2025.06.012","article-title":"Active surveillance for screen-detected low- and intermediate-risk prostate cancer: extended follow-up up to 25 years in the G\u00d6TEBORG-1 trial","volume":"88","author":"Palmstedt","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.01.022_b0015","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","article-title":"Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol","volume":"399","author":"Attard","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2026.01.022_b0020","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.eururo.2013.11.002","article-title":"EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer","volume":"65","author":"Heidenreich","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.01.022_b0025","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","article-title":"Oral relugolix for androgen-deprivation therapy in advanced prostate cancer","volume":"382","author":"Shore","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.01.022_b0030","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.eururo.2024.09.009","article-title":"Testosterone recovery following androgen suppression and prostate radiotherapy (TRANSPORT): a pooled analysis of five randomized trials from the Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium","volume":"87","author":"Ong","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.01.022_b0035","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.eururo.2025.05.013","article-title":"Duration of androgen suppression with postoperative radiotherapy (DADSPORT) for nonmetastatic prostate cancer: a collaborative systematic review and meta-analysis of aggregate data","volume":"88","author":"Burdett","year":"2025","journal-title":"Eur Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826000291?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826000291?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T21:34:24Z","timestamp":1779917664000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283826000291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":7,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0302283826000291"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2026.01.022","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Re: Optimal Duration of Androgen Deprivation Therapy with Definitive Radiotherapy for Localized Prostate Cancer. A Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2026.01.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}